

KIR2DS3 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP5763b**Specification**

KIR2DS3 Antibody (C-term) - Product Information

Application	FC, WB, IHC-P,E
Primary Accession	Q14952
Other Accession	Q8N743 , Q14953 , P43628 , NP_036445.1
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	33717
Antigen Region	268-295

KIR2DS3 Antibody (C-term) - Additional Information**Gene ID** 3808**Other Names**

Killer cell immunoglobulin-like receptor 2DS3, MHC class I NK cell receptor, Natural killer-associated transcript 7, NKAT-7, KIR2DS3, NKAT7

Target/Specificity

This KIR2DS3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 268-295 amino acids from the C-terminal region of human KIR2DS3.

Dilution

FC~~1:10~50

WB~~1:1000

IHC-P~~1:50~100

E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

KIR2DS3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

KIR2DS3 Antibody (C-term) - Protein Information

Name KIR2DS3 ([HGNC:6335](#))

Synonyms NKAT7

Function Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells.

Cellular Location


Cell membrane; Single-pass type I membrane protein

KIR2DS3 Antibody (C-term) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


KIR2DS3 Antibody (C-term) - Images



KIR2DS3 Antibody (C-term) (Cat. #AP5763b) western blot analysis in HL-60 cell line lysates (15ug/lane). This demonstrates the KIR2DS3 antibody detected the KIR2DS3 protein (arrow).



KIR2DS3 Antibody (C-term) (Cat. #AP5763b) immunohistochemistry analysis in formalin fixed and paraffin embedded human spleen tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the KIR2DS3 Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.



KIR2DS3 Antibody (C-term) (Cat. #AP5763b) flow cytometric analysis of HL-60 cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

KIR2DS3 Antibody (C-term) - Background

Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by natural killer cells and subsets of T cells. The KIR genes are polymorphic and highly homologous and they are found in a cluster on chromosome 19q13.4 within the 1 Mb leukocyte receptor complex (LRC). The gene content of the KIR gene cluster varies among haplotypes, although several 'framework' genes are found in all haplotypes (KIR3DL3, KIR3DP1, KIR3DL4, KIR3DL2). The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain transduce inhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM), while KIR proteins with the short cytoplasmic domain lack the ITIM motif and instead associate with the TYRO protein tyrosine kinase binding protein to transduce activating signals. The ligands for several KIR proteins are subsets of HLA class I molecules; thus, KIR proteins are thought to play an important role in

regulation of the immune response.

KIR2DS3 Antibody (C-term) - References

Valiante, N.M., et al. Immunity 7(6):739-751(1997)
Bottino, C., et al. Eur. J. Immunol. 26(8):1816-1824(1996)
Dohring, C., et al. Immunogenetics 44(3):227-230(1996)
Wagtmann, N., et al. Immunity 2(5):439-449(1995)